Signalling in pancreatic cancer: from pathways to therapy

被引：3

作者：

Zhou, Kexun ^{[1
]}

Liu, Yingping ^{[2
]}

Yuan, Shiman ^{[3
]}

Zhou, Ziyu ^{[2
]}

Ji, Pengfei ^{[2
]}

Huang, Qianhan ^{[4
]}

Wen, Feng ^{[1
,5
]}

Li, Qiu ^{[1
,5
]}

机构：

[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu, Peoples R China

[2] Lanzhou Univ, Clin Med Coll 2, Lanzhou, Peoples R China

[3] Guizhou Med Univ, Guiyang, Guizhou, Peoples R China

[4] Xuzhou Med Univ, Sch Publ Hlth, Xuzhou, Peoples R China

[5] Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, 37,Guoxue Xiang, Chengdu 610041, Peoples R China

来源：

JOURNAL OF DRUG TARGETING | 2023年 / 31卷 / 10期

关键词：

Pancreatic cancer; signalling pathways; mechanism; targeted therapy; combined therapy; PHASE-I TRIAL; ACTIVATED PROTEIN-KINASE; GEMCITABINE PLUS PLACEBO; GROWTH-FACTOR RECEPTOR; ORAL MEK INHIBITOR; NF-KAPPA-B; CLINICAL-TRIAL; DOUBLE-BLIND; METASTATIC ADENOCARCINOMA; 1ST-LINE THERAPY;

D O I：

10.1080/1061186X.2023.2274806

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pancreatic cancer (PC) is a common malignant tumour in the digestive system. Due to the lack of sensitive diagnostic markers, strong metastasis ability, and resistance to anti-cancer drugs, the prognosis of PC is inferior. In the past decades, increasing evidence has indicated that the development of PC is closely related to various signalling pathways. With the exploration of RAS-driven, epidermal growth factor receptor, Hedgehog, NF-kappa B, TGF-beta, and NOTCH signalling pathways, breakthroughs have been made to explore the mechanism of pancreatic carcinogenesis, as well as the novel therapies. In this review, we discussed the signalling pathways involved in PC and summarised current targeted agents in the treatment of PC. Furthermore, opportunities and challenges in the exploration of potential therapies targeting signalling pathways were also highlighted.

引用

页码：1013 / 1026

页数：14

共 170 条

[1] Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies [J].

Ardalan, Bach ;

Azqueta, Jose ;

Sleeman, Danny .

JOURNAL OF PANCREATIC CANCER, 2021, 7 (01) :65-70

[2] PhaseIIstudy evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE1) [J].

Assenat, Eric ;

Mineur, Laurent ;

Mollevi, Caroline ;

Lopez-Crapez, Evelyne ;

Lombard-Bohas, Catherine ;

Samalin, Emmanuelle ;

Portales, Fabienne ;

Walter, Thomas ;

de Forges, Helene ;

Dupuy, Marie ;

Boissiere-Michot, Florence ;

Ho-Pun-Cheung, Alexandre ;

Ychou, Marc ;

Mazard, Thibaut .

INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (03) :682-691

[3] Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer [J].

Awasthi, Niranjan ;

Kronenberger, David ;

Stefaniak, Alexis ;

Hassan, Md Sazzad ;

von Holzen, Urs ;

Schwarz, Margaret A. ;

Schwarz, Roderich E. .

CANCER LETTERS, 2019, 459 :41-49

[4] Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer [J].

Bailey, J. M. ;

Mohr, A. M. ;

Hollingsworth, M. A. .

ONCOGENE, 2009, 28 (40) :3513-3525

[5] Hedgehog signaling promotes angiogenesis directly and indirectly in pancreatic cancer [J].

Bausch, Dirk ;

Fritz, Stefan ;

Bolm, Louisa ;

Wellner, Ulrich F. ;

Fernandez-del-Castillo, Carlos ;

Warshaw, Andrew L. ;

Thayer, Sarah P. ;

Liss, Andrew S. .

ANGIOGENESIS, 2020, 23 (03) :479-492

[6] A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors [J].

Bedard, Philippe L. ;

Tabernero, Josep ;

Janku, Filip ;

Wainberg, Zev A. ;

Paz-Ares, Luis ;

Vansteenkiste, Johan ;

Van Cutsem, Eric ;

Perez-Garcia, Jose ;

Stathis, Anastasios ;

Britten, Carolyn D. ;

Le, Ngocdiep ;

Carter, Kirsten ;

Demanse, David ;

Csonka, Denes ;

Peters, Malte ;

Zubel, Angela ;

Nauwelaerts, Heidi ;

Sessa, Cristiana .

CLINICAL CANCER RESEARCH, 2015, 21 (04) :730-738

[7] Key cancer cell signal transduction pathways as therapeutic targets [J].

Bianco, RB ;

Melisi, D ;

Ciardiello, F ;

Tortora, G .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (03) :290-294

[8] Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers [J].

Brauswetter, Diana ;

Gurbi, Bianka ;

Varga, Attila ;

Varkondi, Edit ;

Schwab, Richard ;

Banhegyi, Gabor ;

Fabian, Orsolya ;

Keri, Gyorgy ;

Valyi-Nagy, Istvan ;

Petak, Istvan .

PLOS ONE, 2017, 12 (09)

[9] Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-2-regulated apoptosis in pancreatic cancer cells [J].

Burmi, Rajpal S. ;

Maginn, Elaina N. ;

Gabra, Hani ;

Stronach, Euan A. ;

Wasan, Harpreet S. .

CANCER BIOLOGY & THERAPY, 2019, 20 (01) :21-30

[10] Sonidegib: First Global Approval [J].

Burness, Celeste B. .

DRUGS, 2015, 75 (13) :1559-1566

← 1 2 3 4 5 6 7 8 9 10 →